Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marzeptacog Alfa (Activated) in Inherited Bleeding Disorders
NCT04548791Phase 2Terminated
- Sponsor
- Gyre Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of marzeptacog alfa (activated) in Factor VII deficiency, Glanzmann thrombasthenia (GT), hemophilia A, sponsored by Gyre Therapeutics, Inc.. Started May 2021; status: terminated.
02
Drugs
marzeptacog alfa (activated)
03
Conditions
Factor VII deficiencyGlanzmann thrombasthenia (GT)hemophilia A
Beyond the preview
Go deeper on NCT04548791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548791.